BACKGROUND: EsophyX is an endolumenal approach to the treatment of gastroesophageal reflux disease (GERD). This report describes one of the earliest and largest North American experiences with this device. METHODS: Prospective data were gathered on consecutive patients undergoing EsophyX fundoplication for a 1-year period between September 2007 and March 2009. During this time, the procedure evolved to the current technique. A P value less than 0.05 was considered significant. RESULTS: The study enrolled 26 patients with a mean age of 45 years. The patients included 16 women (62%) with a mean body mass index (BMI) of 28 and an American Society Anesthesiology (ASA) classification of 2. These patients included 11 with associated small hiatal hernias, 3 with Barrett's esophagus, and 5 with esophageal dysmotility. The procedure time was 65 min (range, 29-137 min), and the length of hospital stay was 1 day (range, 0-6 days). The postoperative valve circumference was 217 degrees, and the valve length was 2.7 cm. Two complications of postoperative bleed occurred, requiring transfusion. The mean follow-up period was 10 months. Comparison of pre- and postoperative Anvari scores (34-17; P = 0.002) and Velanovich scores (22-10; P = 0.0007) showed significant decreases. Although 68% of the patients were still taking antireflux medications, 21% had reduced their dose by half. Three patients had persistent symptoms requiring Nissen fundoplication, and there was one late death unrelated to the procedure. CONCLUSION: This study represents an initial single-institution experience with EsophyX. According to the findings, 53% of the patients had either discontinued their antireflux medication (32%) or had decreased their dose by half (21%). Both symptoms and health-related quality-of-life (HRQL) scores significantly improved after treatment. Further follow-up evaluation and objective testing are required.
BACKGROUND: EsophyX is an endolumenal approach to the treatment of gastroesophageal reflux disease (GERD). This report describes one of the earliest and largest North American experiences with this device. METHODS: Prospective data were gathered on consecutive patients undergoing EsophyX fundoplication for a 1-year period between September 2007 and March 2009. During this time, the procedure evolved to the current technique. A P value less than 0.05 was considered significant. RESULTS: The study enrolled 26 patients with a mean age of 45 years. The patients included 16 women (62%) with a mean body mass index (BMI) of 28 and an American Society Anesthesiology (ASA) classification of 2. These patients included 11 with associated small hiatal hernias, 3 with Barrett's esophagus, and 5 with esophageal dysmotility. The procedure time was 65 min (range, 29-137 min), and the length of hospital stay was 1 day (range, 0-6 days). The postoperative valve circumference was 217 degrees, and the valve length was 2.7 cm. Two complications of postoperative bleed occurred, requiring transfusion. The mean follow-up period was 10 months. Comparison of pre- and postoperative Anvari scores (34-17; P = 0.002) and Velanovich scores (22-10; P = 0.0007) showed significant decreases. Although 68% of the patients were still taking antireflux medications, 21% had reduced their dose by half. Three patients had persistent symptoms requiring Nissen fundoplication, and there was one late death unrelated to the procedure. CONCLUSION: This study represents an initial single-institution experience with EsophyX. According to the findings, 53% of the patients had either discontinued their antireflux medication (32%) or had decreased their dose by half (21%). Both symptoms and health-related quality-of-life (HRQL) scores significantly improved after treatment. Further follow-up evaluation and objective testing are required.
Authors: G B Cadière; A Rajan; M Rqibate; O Germay; G Dapri; J Himpens; A K Gawlicka Journal: Minim Invasive Ther Allied Technol Date: 2006 Impact factor: 2.442
Authors: Guy-Bernard Cadière; Nathalie Van Sante; Jaime E Graves; Anna K Gawlicka; Amin Rajan Journal: Surg Endosc Date: 2009-03-14 Impact factor: 4.584
Authors: Simon Bergman; Dean J Mikami; Jeffrey W Hazey; Jason C Roland; Rebecca Dettorre; W Scott Melvin Journal: Surg Innov Date: 2008-09 Impact factor: 2.058
Authors: Toshitaka Hoppo; Arul Immanuel; Matthew Schuchert; Zdenek Dubrava; Andrew Smith; Peter Nottle; David I Watson; Blair A Jobe Journal: J Gastrointest Surg Date: 2010-09-28 Impact factor: 3.452
Authors: Bart P L Witteman; Jose M Conchillo; Nicolaas F Rinsma; Bark Betzel; Andrea Peeters; Ger H Koek; Laurents P S Stassen; Nicole D Bouvy Journal: Am J Gastroenterol Date: 2015-03-31 Impact factor: 10.864